THY1 and cancer: In order to validate the hypothesis that THY1 is related to cancer stemness and immunotherapy resistance, we performed IHC staining on six tissue samples of LUAD patients who received at least three cycles of PD-1 mAb treatments using THY1 and SOX9 antibodies.